About The Study

This study is for those with Type 2 Diabetes and scarring of the liver due to NASH (non-alcoholic steatohepatitis). NASH is also sometimes called “fatty liver.” Many people have a build-up of fat in the liver, and for most people, it causes no symptoms and no problems. But in some people, the fat causes inflammation and damages cells in the liver. NASH can be caused by conditions such as excess weight or other metabolic conditions when combined with certain diets and genetic backgrounds. Fatty liver is the most common cause of chronic liver disease in North America. There is currently no approved medication to help fatty liver.

Qualified participants in this study will receive a once-weekly investigational injection..

Qualified participants have a 2 out of 3 chance of receiving the study drug, or a 1 out of 3 chance of placebo. The goal of the study is to see if the study drug will help in the treatment of NASH and liver fibrosis.

To take part in the study, participants should be:

• Diagnosed with NASH (or ‘Fatty Liver’) and fibrosis
• Between 18 – 80 years old
• Diagnosed with Type 2 Diabetes
• Have 2 out of 4 components of metabolic syndrome (obesity, dyslipidemia, elevated blood pressure, elevated fasting glucose)
• A BMI of 25 and greater
• Meet other study criteria